60 page Review of Merck's Oncology Pipeline, spotlighting precemtabart tocentecan (main indication: colorectal cancer), and Neurology & Immunology Pipeline, spotlighting enpatoran (lupus rash) and cladrbine capsules (generalized myesthenia gravis), contextualized with on-market Healthcare portfolio
